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(ELW), extravascular plasma equivalents, permeability index, myeloperoxidase activity) were assessed
and lungs were homogenized for Western blot analysis of phosphorylated and total Src, ICAM-1 and
caveolin-1. Additional experiments evaluated effects of ropivacaine on LPS-induced phosphorylation/-
expression of Src, ICAM-1 and caveolin-1 in human lung microvascular endothelial cells (HLMVEC).
RESULTS: WT mice treated with LPS alone showed a 49% increase in ELW compared to control an-
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lung homogenates as well as HLMVEC treated in culture with LPS alone showed a reduction in Src
activation/expression, as well as ICAM-1 expression and caveolin-1 phosphorylation. In ICAM-1 (-/-)
mice, neither addition of LPS to HTV ventilation alone nor ropivacaine had an effect on the development
of ALI. CONCLUSIONS: Ropivacaine may be a promising therapeutic agent for treating the cause of
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Abstract
Background: Acute lung injury (ALI) is associated with high mortality due to the lack of effective therapeutic
strategies. Mechanical ventilation itself can cause ventilator-induced lung injury. Pulmonary vascular barrier function,
regulated in part by Src kinase-dependent phosphorylation of caveolin-1 and intercellular adhesion molecule-1
(ICAM-1), plays a crucial role in the development of protein-/neutrophil-rich pulmonary edema, the hallmark of ALI.
Amide-linked local anesthetics, such as ropivacaine, have anti-inflammatory properties in experimental ALI. We
hypothesized ropivacaine may attenuate inflammation in a “double-hit” model of ALI triggered by bacterial
endotoxin plus hyperinflation via inhibition of Src-dependent signaling.
Methods: C57BL/6 (WT) and ICAM-1−/− mice were exposed to either nebulized normal saline (NS) or
lipopolysaccharide (LPS, 10 mg) for 1 hour. An intravenous bolus of 0.33 mg/kg ropivacaine or vehicle was followed
by mechanical ventilation with normal (7 ml/kg, NTV) or high tidal volume (28 ml/kg, HTV) for 2 hours. Measures of
ALI (excess lung water (ELW), extravascular plasma equivalents, permeability index, myeloperoxidase activity) were
assessed and lungs were homogenized for Western blot analysis of phosphorylated and total Src, ICAM-1 and
caveolin-1. Additional experiments evaluated effects of ropivacaine on LPS-induced phosphorylation/expression of
Src, ICAM-1 and caveolin-1 in human lung microvascular endothelial cells (HLMVEC).
Results: WT mice treated with LPS alone showed a 49% increase in ELW compared to control animals (p = 0.001),
which was attenuated by ropivacaine (p = 0.001). HTV ventilation alone increased measures of ALI even more than
LPS, an effect which was not altered by ropivacaine. LPS plus hyperinflation (“double-hit”) increased all ALI
parameters (ELW, EVPE, permeability index, MPO activity) by 3–4 fold compared to control, which were again
decreased by ropivacaine. Western blot analyses of lung homogenates as well as HLMVEC treated in culture with LPS
alone showed a reduction in Src activation/expression, as well as ICAM-1 expression and caveolin-1 phosphorylation.
In ICAM-1−/− mice, neither addition of LPS to HTV ventilation alone nor ropivacaine had an effect on the development
of ALI.
Conclusions: Ropivacaine may be a promising therapeutic agent for treating the cause of pulmonary edema by
blocking inflammatory Src signaling, ICAM-1 expression, leukocyte infiltration, and vascular hyperpermeability.
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Background
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are associated with high morbidity and
mortality [1,2]. Treatment options are largely supportive
(e.g. lung-protective ventilation) [3] and thus there is a
need for effective anti-inflammatory strategies that treat
pulmonary endothelial hyperpermeability, a hallmark of
the disease. Despite the necessity of mechanical ven-
tilation in the supportive management of ALI or ARDS,
ventilation per se can also contribute to lung injury (i.e.,
ventilator-induced lung injury, or VILI) [4]. Large tidal
volumes, high inspiratory pressures, and/or high levels of
positive end-expiratory pressure lead to a protein-
and neutrophil-rich permeability-type pulmonary edema,
similar to that occurring in ALI [5]. Experimental data
also suggests that VILI is even more severe when induced
in combination with bacterial endotoxin, as exemplified in
the “double-hit” mouse model of ALI/VILI [6].
Local anesthetics are widely used in clinical practice
for local, regional and neuraxial anesthesia, as well as for
peri- and postoperative pain control [7,8]. In addition,
they have also been demonstrated to exhibit significant
anti-inflammatory properties [9-11]. In an earlier study
of bacterial endotoxin-induced lung injury, it was shown
that administration of the long-acting amide-linked local
anesthetic ropivacaine attenuated endothelial cell NFκB
activation and inflammatory lung injury in vivo and lung
epithelial cell activation in vitro [9].
Src protein tyrosine kinase (Src) is known to regulate
endothelial barrier function and to play a key role in me-
diating inflammatory vascular hyperpermeability in vitro
[12]. Intercellular adhesion molecule-1 (ICAM-1), a cell
surface molecule of the immunoglobulin superfamily,
mediates firm adhesion of circulating neutrophils and
thereby enhances their transmigration through the endo-
thelial barrier. ICAM-1 is phosphorylated by Src on tyro-
sine 512 (human; tyrosine 518 in mice) [13,14] during
pulmonary vascular inflammation and is thought to play
an important role in the mechanism of ALI and ARDS
[14-16]. Additionally, Src-dependent phosphorylation of
caveolin-1 on tyrosine 14, which is known to promote the
transcellular transport of albumin via caveolae [17] as well
as regulate downstream signaling that can lead to disrup-
tion of adherens junctions [18], also contributes signifi-
cantly to the development of ALI [12,19,20].
In the present study, we hypothesized that the local
anesthetic ropivacaine, at clinically relevant concentra-
tions, may have anti-inflammatory properties by blocking
endotoxin-induced Src signaling in mice and cultured
human endothelial cells. We tested the hypothesis that
ropivacaine attenuates lung injury/inflammatory hyper-
permeability in the mouse induced by either high tidal
volume (HTV) ventilation or bacterial endotoxin alone,
versus the “double-hit” model of HTV ventilation together
with bacterial endotoxin [6]. In these experiments, we
assessed whether anti-inflammatory effects were mediated
by reducing Src-dependent phosphorylation of ICAM-1
and caveolin-1 in endothelial cells, thereby blocking in-
flammatory hyper-permeability [12].
Methods
Animals
All animal experiments were approved by the University
of Illinois Institutional Animal Care and Use Committee
(IACUC). Mice were housed in the mouse barrier facility
at UIC and were allowed full access to food and water
until the time of the experiment. Two strains of mice
were used in this study, wild-type C57BL/6 (WT) and
strain-matched ICAM-1 knockout (ICAM-1−/−) mice.
Animal protocol
To evaluate the effects of ropivacaine on acute lung injury
as induced by high tidal volume ventilation or endotoxin,
as well as by the “double-hit” with endotoxin and VILI,
mice were exposed to either nebulized normal saline (NS,
0.9% sodium chloride solution, Hospira, Lake Forest, IL)
or 10 mg nebulized Escherichia coli serotype 055:B5
lipopolysaccharide diluted in NS (LPS, Sigma-Aldrich,
St. Louis, MO) for 1 hour. During the second hour of the
protocol, anesthesia was induced via intraperitoneal in-
jection of 100 mg/kg ketamine (Hospira) and 5 mg/kg
xylazine (Lloyd Laboratories, Shenandoah, IA) and a PE10
catheter was inserted into the right internal jugular vein.
Two hours after the start of the experiment, mice received
a 30 μl intravenous bolus of either NS or ropivacaine (R) at
1 mM concentration (Naropin®, APP Pharmaceuticals,
Schaumburg, IL) diluted in NS solution. The total amount
of administered drug was therefore 0.01 mg, or 0.33 mg/kg
in a 30 g mouse. Mice were then subjected to volume-
controlled mechanical ventilation via a tracheostomy with
either a normal tidal volume of 7 ml/kg (NTV) or high
tidal volume of 28 ml/kg (HTV) to induce VILI [21-23].
Mice were randomly assigned to one of eight groups (n = 7
each) as shown in Figure 1: 1) Nebulized NS, intravenous
NS, NTV ventilation (NS-NS-NTV; control), 2) NS-R-
NTV, 3) LPS-NS-NTV, 4) LPS-R-NTV, 5) NS-NS-HTV, 6)
NS-R-HTV, 7) LPS-NS-HTV, 8) LPS-R-HTV. Mice were
given an additional intraperitoneal ketamine/xylazine in-
jection (half of initial dose) 1 hour after the initiation of
mechanical ventilation to maintain anesthesia. Normother-
mia (37°C to 38°C) was maintained using a heating lamp.
Excess lung water (ELW), extravascular plasma
equivalents (EVPE), permeability index
One hour before the end of the experiment, mice received
an intravenous injection of radioactive-labeled albumin
(1 μC I125-albumin). At the end of the experiment, the
body weight of the animal was determined and a blood
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sample was collected, either via a retro-orbital approach or
by puncturing the inferior vena cava after opening up the
abdominal cavity, and hematocrit was determined (IEC
MB Centrifuge, Damon, Needham Heights, MA). An
additional 400 – 500 μl of blood was collected in tubes
containing ethylenediaminetetraacetic acid (EDTA; BD
Biosciences, Franklin Lakes, NJ). The lungs were then
excised in total, placed into pre-weighed 5 ml plastic tubes
(BD Biosciences) and immediately covered to prevent
evaporation. After initial weighing of the tube together
with the lung, we added 1 ml of ultrapure water and re-
weighed the containers. The lungs were then homogenized
with a Kinematica Polytron homogenizer (Fisher Scientific,
Pittsburgh, PA). A 0.25 ml aliquot of lung homogenate
was sedimented at 13000 rpm for 10 min (Eppendorf
5415R microcentrifuge, Eppendorf, Hamburg, Germany).
Hemoglobin concentration was measured in both the
supernatant of the homogenate and the anti-coagulated
whole blood sample with a Hb 201 analyzer (Hemocue,
Cypress, CA). Total lung homogenate (150 μl, before cen-
trifugation), supernatant, and a whole blood sample were
then put in pre-weighed aluminum dishes and weighed.
The dishes were then placed in a drying oven (60°C) for at
least 24 hours, after which the dried samples were weighed
again.
ELW was then calculated as described by Su et al. [24]:
First, we calculated the water fraction in the lung hom-
ogenate (WFh), the supernatant of the homogenate (WFs)
and the whole blood sample (WFb) using the formula
WF ¼ Wwet– Wdry
 
= Wwet ;
with Wwet representing the wet weight and Wdry being
the dry weight.
We then calculated the blood volume found in the
lung:
Qb ¼ 1:039 x Qhx WFhx Hbsð Þ = WFsx Hbbð Þ
The number of 1.039 is the density of blood, Qh denotes
the lung homogenate weight (=whole lung wet weight +
weight of ultrapure water), Hbs represents the hemoglobin
concentration in the homogenate supernatant, and Hbb
the hemoglobin concentration of the whole blood sample.
The calculation of the volume of water in the lung was
executed with the following formula:
Qw ¼ Qhx WFhð Þ – Qbx WFbð Þ – Ww:
Here, Ww represents the weight of the ultrapure water
added before the homogenization of lung tissue (see
above).
The calculation of the whole lung dry weight (Qd) was
also necessary:
Qd ¼ whole lung wet weight – Qw– Qb
Finally, ELW was calculated as follows:
ELW ¼ Qw exp= Qd expx Qdexp
 
x Qw control= Qd controlx Qd controlð Þ
n o
x 1000 μlð Þ:
Qw exp is the volume of water found in the lung of ex-
perimental animals and Qd exp is the dry weight of the
lung in the experimental animals. Mice of the same age
as the experimental groups served as controls.
For EVPE, we additionally assessed radioactivity of both
100 μl whole blood and the whole lung immersed in 1 ml
of water before homogenization in a γ-counter chamber
(Perkin Elmer, Waltham, MA). Measured counts per
Figure 1 Schematic illustration of the workflow of animal experiments. C57BL/6 mice (WT) were exposed to either normal saline (NS) or
nebulized LPS (10 mg) for 1 hour. Induction of anesthesia with ketamine/xylazine (Ket/Xyl) during the second hour of the experiment was
followed by the insertion of a central venous catheter into the right or left internal jugular vein and the application of an intravenous bolus of
either 0.01 mg ropivacaine (ropi in the figure, R in the group description) or vehicle (normal saline, NS). Mice were then mechanically ventilated
for 2 hours via a tracheostomy with either normal tidal volumes (7 ml/kg, NTV) or high tidal volumes (28 ml/kg, HTV). Mice were randomized into
8 different groups (n = 7 each): 1) Nebulized NS, intravenous NS, NTV ventilation (NS-NS-NTV; control), 2) NS-R-NTV, 3) LPS-NS-NTV, 4) LPS-R-NTV,
5) NS-NS-HTV, 6) NS-R-HTV, 7) LPS-NS-HTV, 8) LPS-R-HTV.
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minute were then normalized per gram (cpg) and used in
the formula to determine EVPE as follows:
EVPE ¼ blood free lung tissue cpg = plasma cpg x 1000ð Þ½ :
For the calculation of the endothelial permeability
index, we first calculated the plasma volume:
Plasma Volume ¼ body weightð Þ x 1 – Hematocritð Þ x 0:007 x 1000½ :
The results from this calculation were used to deter-
mine the permeability index:
Endothelial permeability ¼ ½blood−free lung tissue cpg
= plasma cpg x plasma volumeð Þ
x 100 %ð Þ:
Myeloperoxidase activity
Myeloperoxidase (MPO) activity in lung homogenates
was used as a surrogate marker of neutrophil extravasa-
tion and sequestration as previously described [6,25].
Lung homogenates for Western blot analysis
Whole lungs of animals from the different treatment
groups were removed at the end of the experiment, imme-
diately snap-frozen in liquid nitrogen, and stored at −80°C
until further processing. Equal lung parts were then
immersed in lysis buffer (0.4 M Tris–HCl pH 7.5, 0.14 M
NaCl, 1.5% Triton X-100, 0.5% desoxycholic acid, 0.1% so-
dium dodecyl sulfate, protease inhibitor cocktail, 200 mM
phenylmethylsulfonylfluoride, 1 mM EDTA, 1 mM so-
dium-fluoride, and 1 mM sodium-orthovanadate) and
homogenized on ice. After a 30-minute incubation to
allow protein dissociation, the homogenates were centri-
fuged for 20 minutes at 16,000 rpm to remove debris. The
supernatant was collected and stored at −80°C until fur-
ther use.
Cell cultures and in vitro experimental procedures
Human lung microvascular endothelial cells (HLMVEC,
Lonza, Walkersville, MD) were cultured in VascuLife Basal
medium supplemented with the VascuLife VEGF-Mv Life-
Factors kit (both from LifeLine Cell Technology, Frederick,
MD) containing 5% fetal bovine serum, 10 mM L-glutam-
ine, 5 ng/ml recombinant human (rh) vascular endothelial
growth factor (VEGF), 5 ng/ml rh epidermal growth factor
(EGF), 5 ng/ml rh fibroblast growth factor (FGF), 15 ng/ml
rh insulin-like growth factor 1 (IGF-1), 1 μg/ml hydrocor-
tisone hemisuccinate, 0.75 U/ml heparin, and 50 μg/ml
ascorbic acid. All cell culture dishes, plates and flasks were
coated with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO)
diluted in Dulbecco’s phosphate buffered saline without
calcium and magnesium (Cellgro, Manassas, VA). Experi-
ments were performed in 90 – 100% confluent cells from
passages 5 – 12. Before the experiments, cells were grown
in VascuLife Basal Medium without supplements for
16 hours. Cells were kept in 5% CO2 and 95% room air in
a water-jacketed incubator at 37°C.
HLMVEC monolayers were incubated with Escherichia
coli serotype 055:B5 lipopolysaccharide (LPS, Sigma-
Aldrich, St. Louis, MO) at a concentration of 4 μg/ml
diluted in VascuLife Basal Medium for 4 hours. Ropiva-
caine 0.5% was also diluted in VascuLife Basal Medium in
order to be able to test several concentrations of the drug
(1 nM, 1 μM, 10 μM, 100 μM) in the absence or presence
of LPS. For some experiments, cells were pretreated
for 30 minutes with the Src kinase inhibitor 4-amino-5-
(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d] pyri-
midine (PP2; 10 μM) dissolved in dimethylsulfoxide
(DMSO, Sigma-Aldrich) or with DMSO alone as the
vehicle control (0.1%) prior to addition of LPS.
Cell harvest and lysis
At the end of the experiment, HLMVEC were harvested
and lysed with radio-immunoprecipitation buffer (Boston
Bioproducts, Ashland, MA), supplemented with protease
inhibitor cocktail, 200 mM phenylmethylsulfonylfluoride,
1 mM EDTA, 1 mM sodium-fluoride, and 1 mM sodium-
orthovanadate (all from Sigma-Aldrich) as previously de-
scribed [26,27].
Determination of total protein concentration
Total protein concentration of lung homogenates and
whole cell lysates was measured by DC Protein Assay
Kit (BioRad, Hercules, CA) according to the manufac-
turer’s instructions; immunoglobulin G was used for de-
termination of the standard curve.
Western blot
Western blot analysis of either lung homogenates or whole
cell lysates was carried out as previously described [26,27].
Antibodies against pY419 Src and total Src were purchased
from Cell Signaling Technologies (Danvers, MA), for
pY512 ICAM-1 and total ICAM-1 from Santa Cruz
Biotechnology (Santa Cruz, CA), and for pY14 caveolin-1,
total caveolin-1, and β-actin from BD Biosciences (Franklin
Lakes, NJ).
Statistical analysis
First, normal distribution was assessed using a Shapiro-
Wilk test. Normally distributed data was then subject to
analysis by ANOVA followed by Bonferroni post-hoc testing
to maintain the family-wise error rate <0.05. Not-normally
distributed data was analyzed with non-parametric testing
methods (Kruskal-Wallis and Mann–Whitney U tests)
with Dunn’s post-hoc correction. The in vivo measures of
ALI (ELW, EVPE, Permeability, MPO activity) were com-
pared as two separate sets of data: one between the groups
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that were subject to NTV ventilation and one between the
groups that had received HTV ventilation. In both cases,
the NS-NS-NTV group served as the control group.
Experimental data are presented as mean ± standard
deviation (SD). All tests were performed two-sided and
non-blinded with GraphPad Prism for Mac, Version 6
(GraphPad Software, La Jolla, CA). A p-value of <0.05 was
considered to be statistically significant.
Results
Ropivacaine attenuates measures of ALI triggered by
bacterial endotoxin and hyperinflation
To assess the influence of ropivacaine administration on
the degree of ALI induced by endotoxin or HTV alone
vs the “double-hit” model (see Figure 1), we measured
ELW, EVPE and permeability index. Additionally, the
activity of neutrophil MPO in lung homogenates was
evaluated as an index of lung inflammation.
Treatment with LPS alone (LPS-NS-NTV) led to a 49%
increase in ELW compared to control animals (NS-NS-
NTV; p = 0.001, Figure 2A) which was significantly atte-
nuated by ropivacaine (LPS-R-NTV group; p = 0.001).
However, WT animals ventilated with HTV (NS-NS-HTV)
also showed a significant increase in ELW compared to
control animals (NS-NS-NTV; p = 0.005), however this
effect was not altered by ropivacaine (NS-R-HTV group;
p = 1). If mice were exposed to LPS prior to mechanical
ventilation with HTV (LPS-NS-HTV), we observed a
2-fold increase in ELW compared to HTV alone (NS-NS-
HTV; p < 0.001) and a 3.5-fold increase compared to con-
trol (NS-NS-NTV; p < 0.001). Ropivacaine (LPS-R-HTV
group) significantly decreased the “double-hit” inflamma-
tory response by 28% (p = 0.001; Figure 2A).
To further evaluate the effect of HTV ventilation, LPS,
and ropivacaine on endothelial barrier function, changes
in EVPE (Figure 2B) and permeability index were assessed
(Figure 2C). These measures, which are based on the ac-
cumulation of radioactive 125I-albumin in the lungs, quan-
titatively assess endothelial barrier function in vivo during
ALI. The two parameters showed patterns similar to that
of ELW, except for the fact that there were no significant
differences between the groups which were subject to
NTV ventilation (p = 0.091 for EVPE; p = 0.113 for perme-
ability, Figures 2B and 2C). HTV ventilation, on the other
hand, induced a significant increase in EVPE and perme-
ability compared to control WT mice (p = 0.006 for EVPE;
p = 0.035 for permeability) and neither were altered by
ropivacaine (p = 1 for both comparisons). LPS exposure
Figure 2 Effect of ropivacaine on acute lung injury. Acute lung injury was induced by either hyperinflation (HTV), bacterial lipopolysaccharide
(LPS), or a combination of the two (“double-hit” model) in C57BL/6 wild type (C57 WT) mice. ALI was assessed by measuring (A) Excess lung
water (ELW), (B) extravascular plasma equivalents (EVPE), (C) permeability index, and (D) myeloperoxidase activity as described in Methods. Values
shown are mean ± SD (n = 7); #p < 0.05 vs. control (NS-NS-HTV); *p < 0.05 vs. LPS-NS-HTV.
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prior to HTV ventilation significantly increased EVPE and
permeability index compared to control (p < 0.001 for EVPE
and permeability) and HTV ventilation alone (p = 0.017 for
EVPE; p = 0.004 for permeability), and this LPS-induced in-
crease was attenuated significantly by ropivacaine (p = 0.039
for EVPE; p = 0.042 for permeability).
To assess the amount of neutrophil transmigration
into the interstitial and alveolar spaces, MPO activity in
lung homogenates was measured. Here, both LPS and
ropivacaine led to a slight increase in MPO activity com-
pared to control in mice that were subsequently venti-
lated with NTV (p = 0.02 for LPS-R-NTV, p = 0.027 for
NS-R-NTV, Figure 2D). However, there was no diffe-
rence in MPO activity between control animals and
those exposed to LPS and ropivacaine followed by NTV
ventilation (p = 0.692). After HTV ventilation alone,
there was a 7-fold increase in MPO activity compared to
control (p = 0.001; Figure 2D) which was not affected by
ropivacaine (NS-R-HTV group; p = 1). LPS exposure be-
fore HTV ventilation increased MPO activity even more
(9-fold over control; p < 0.001), which was significantly
reduced in mice treated with ropivacaine (p = 0.013;
Figure 2D).
Effect of ropivacaine on Src, ICAM-1 and caveolin-1 in
lung homogenates of mice challenged with endotoxin
alone
In order to investigate the anti-inflammatory mechanism
by which ropivacaine reduced edema formation (ELW) in
mice following treatment with aerosolized LPS, we mea-
sured the phosphorylation status and expression levels
of Src (Figure 3A), ICAM-1 (Figure 3B) and caveolin-1
(Figure 3C) via Western blot analysis. Src activation,
expressed as the ratio of Src, phosphorylated at tyrosine
418, over total Src (Figure 3Aii) was on average 2-fold
higher in lungs treated with LPS alone as compared to
control animals, however, this effect did not reach statis-
tical significance (n = 5, p = 1). Treatment with ropivacaine
together with LPS significantly decreased Src activation
compared to treatment with LPS alone (p = 0.018). There
were no differences in Src expression between the groups
subjected to NTV ventilation (p = 0.64, Figure 3Aiii).
Similar results were obtained for the expression and
phosphorylation of ICAM-1 at tyrosine 518, expressed as
a ratio of the phosphorylated protein over the total
amount of ICAM-1. Expression levels were not altered by
any of the treatments prior to NTV ventilation (p = 0.451,
Figure 3Biii), but there was a non-significant increase of
80% in ICAM-1 phosphorylation after exposure to LPS
compared to control (p = 0.325) which was completely
abolished by ropivacaine (p = 0.018, Figure 3Bii).
No significant changes in either caveolin-1 phosphory-
lation (expressed as the ratio of caveolin-1, phosphory-
lated at tyrosine 14 over the total amount of caveolin-1,
Figure 3Cii, p = 0.466) or expression (p = 0.874, Figure 3Ciii)
were detected (Figures 3Cii and 3Ciii).
Effect of ropivacaine on Src, ICAM-1 and caveolin-1 in
lung homogenates of mice challenged with both
endotoxin and hyperinflation
To assess the anti-inflammatory mechanism of ropiva-
caine in the “double-hit” mouse model of ALI, we again
measured the phosphorylation status and expression levels
of Src, ICAM-1 and caveolin-1 via Western blot analysis
in lung homogenates of WT mice treated with HTV venti-
lation +/− LPS and +/− ropivacaine as described above
(representative blots shown in Figures 4Ai, 4Bi and 4Ci).
Densitometry analysis (n = 12-14) showed no significant
changes in Src activation at the 4 hour time point after
HTV alone (Figure 4Aii) compared to control (p = 1). The
application of ropivacaine before HTV ventilation reduced
Src-pTyr418/Src by 37% compared to HTV alone, however,
this effect was not statistically significant (p = 0.678). Src
expression in lung homogenates (Figure 4Aiii) doubled in
both the NS-NS-HTV and the LPS-NS-HTV groups com-
pared to control (p = 0.024 and p = 0.045, respectively). In
both settings – with or without LPS – the addition of
ropivacaine completely abolished the observed increase in
Src expression (p = 0.012 for NS-R-HTV and p = 0.026 for
LPS-R-HTV; Figure 4Aiii). Similar results were obtained
for ICAM-1 phosphorylation (Figure 4Bii); neither HTV
ventilation alone nor LPS plus HTV were different from
control (p = 1 for both comparisons).
Lung tissue ICAM-1 expression (Figure 4Biii), how-
ever, increased by 259% compared to control following
HTV ventilation (p = 0.006) and this increase was com-
pletely blocked by ropivacaine (p = 0.004). LPS plus
HTV ventilation increased ICAM-1 expression to about
the same extent as HTV ventilation alone (LPS-NS-
HTV, p = 0.001 vs. control), which again was reduced
by 73% in mice treated with ropivacaine (LPS-R-HTV,
p = 0.04).
Whereas no effect of ropivacaine was observed on Src
and ICAM-1 phosphorylation, caveolin-1 phosphory-
lation at tyrosine 14 could be blocked by ropivacaine
(Figure 4Cii). Ropivacaine plus subsequent HTV ven-
tilation (NS-R-HTV) decreased Cav-1-pTyr14/Cav-1 by
51% compared to HTV ventilation alone (p < 0.001),
and in addition, blocked LPS/HTV-induced increase in
Cav-1 phosphorylation (p < 0.001; Figure 4Cii). The ex-
pression of caveolin-1 (Cav-1) did not change in any of
the treatment groups (p = 0.501, Figure 4Ciii).
Requirement of ICAM-1 in mediating acute lung injury in
the double-hit mouse model
To further characterize the mechanism of the anti-
inflammatory effect of ropivacaine in the double-hit
mouse model of ALI, additional experiments in
Piegeler et al. BMC Anesthesiology 2014, 14:57 Page 6 of 14
http://www.biomedcentral.com/1471-2253/14/57
ICAM-1−/− mice using the same procedures as de-
scribed for WT animals were performed. As shown in
Figure 5A-D, a significant increase in all measures of
ALI (ELW, EVPE, permeability, and MPO activity) in-
duced by HTV ventilation alone in ICAM-1−/− mice
was observed. However, unlike that which was noted
in WT mice, LPS did not further increase lung inflamma-
tion or permeability, and interestingly, ropivacaine had no
effect in ICAM-1−/− mice. As there was no significant
effect of ropivacaine on ALI in ICAM-1−/− mice, Western
blot analyses of the lungs of these animals were not
performed.
Figure 3 Effect of ropivacaine on phosphorylation and expression of Src, ICAM-1, and caveolin-1 in the mouse lung during ALI as
induced by LPS. Src protein tyrosine kinase (Src) and its substrates intercellular adhesion molecule-1 (ICAM-1) and caveolin-1 in mouse lung
homogenates were assessed after induction of acute lung injury with bacterial lipopolysaccharide (LPS) in C57BL/6 wild type mice. (A.) (i.) Representative
Western Blot of lung homogenates probing for Src tyrosine kinase, phosphorylated at tyrosine 418 (pTyr418-Src), total Src as well as β-actin. Quantitative
densitometry analysis of Western blots showing (ii.) the ratio of pTyr418-Src over total Src compared to control animals (set as 1.0, white bars; N = 5/
group), and (iii.) Src expression as a ratio of total Src over β-actin compared to control animals (set as 1.0, white bars; N = 5/group). (B.) (i.) Representative
Western Blot of lung homogenates probing for ICAM-1, phosphorylated at tyrosine 518 (pTyr518-ICAM-1), total ICAM-1, as well as β-actin. Quantitative
densitometry analysis showing (ii.) the ratio of pTyr518-ICAM-1 over total ICAM-1 compared to control animals (set as 1.0, white bars; N = 5/group),
(iii.) ICAM-1 expression as the ratio of total ICAM-1 over β-actin compared to control animals (set as 1.0, white bars; N = 5/group). (C.) (i.) Representative
Western Blot of lung homogenates probing for caveolin-1, phosphorylated at tyrosine 14 (pTyr14-Cav-1), total Cav-1 as well as β-actin. Quantitative
densitometry analysis showing (ii.) the ratio of pTyr14 Cav-1 over total Cav-1 compared to control animals (set as 1.0, white bars; N = 5/group), and
(iii.) Cav-1 expression as a ratio of total Cav-1 over β-actin compared to control animals (set as 1.0, white bars; N = 5/group). All values shown are mean
± SD; #p < 0.05 vs. control (NS-NS-HTV); *p< 0.05 compared to LPS alone.
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Effect of ropivacaine on endotoxin-induced changes in
expression/phosphorylation of Src, ICAM-1 and caveolin-1
in cultured human lung microvascular endothelial cells
(HLMVECs)
Ropivacaine blocks LPS-induced Src activation and
expression in HLMVECs
To determine whether the anti-inflammatory and barrier
protective effects of ropivacaine observed in LPS-treated
WT mouse lungs were due to direct effects of ropivacaine
on the endothelium, HLMVEC were incubated with LPS at
a concentration of 4 μg/ml for 4 hours in presence or ab-
sence of ropivacaine at a concentration of 1 nM (10−9 M).
Analysis of whole cell lysates was conducted via Western
blot, probing for pTyr419 Src, total Src, and β-actin
(Figure 6Ai). These studies showed that LPS-induced in-
crease in Src activity (69%, p = 0.022; Figure 6Aii) and
Figure 4 Effect of ropivacaine on phosphorylation and expression of Src, ICAM-1, and caveolin-1 in the mouse lung during ALI as induced
by LPS and hyperinflation (“double-hit” model). Src protein tyrosine kinase (Src) and its substrates intercellular adhesion molecule-1 (ICAM-1) and
caveolin-1 in mouse lung homogenates were assessed after induction of acute lung injury with either hyperinflation (HTV) or a combination of bacterial
lipopolysaccharide (LPS) with HTV ventilation (“double-hit” model) in C57BL/6 wild type mice. (A.) (i.) Representative Western Blot of lung homogenates
probing for Src tyrosine kinase, phosphorylated at tyrosine 418 (pTyr418-Src), total Src as well as β-actin. Quantitative densitometry analysis of Western
blots showing (ii.) the ratio of pTyr418-Src over total Src compared to control animals (set as 1.0, white bars; N = 13/group), and (iii.) Src expression as a
ratio of total Src over β-actin compared to control animals (set as 1.0, white bars; N = 13/group). (B.) (i.) Representative Western Blot of lung homogenates
probing for ICAM-1, phosphorylated at tyrosine 518 (pTyr518-ICAM-1), total ICAM-1, as well as β-actin. Quantitative densitometry analysis showing (ii.) the
ratio of pTyr518-ICAM-1 over total ICAM-1 compared to control animals (set as 1.0, white bars; N = 12/group), (iii.) ICAM-1 expression as the ratio of total
ICAM-1 over β-actin compared to control animals (set as 1.0, white bars; N = 12/group). (C.) (i.) Representative Western Blot of lung homogenates probing
for caveolin-1, phosphorylated at tyrosine 14 (pTyr14-Cav-1), total Cav-1 as well as β-actin. Quantitative densitometry analysis showing (ii.) the ratio of
pTyr14 Cav-1 over total Cav-1 compared to control animals (set as 1.0, white bars; N = 10/group), and (iii.) Cav-1 expression as a ratio of total Cav-1 over
β-actin compared to control animals (set as 1.0, white bars; N = 13/group). All values shown are mean ± SD; #p < 0.05 vs. control (NS-NS-HTV); *p< 0.05
compared to group as indicated.
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expression (71%, p = 0.019, Figure 6Aiii) were completely
blocked by 1 nM ropivacaine (p = 0.001 for Src activation,
Figure 6Aii; p < 0.001 for Src expression, Figure 6Aiii).
Ropivacaine attenuates LPS-induced ICAM-1 expression in
HLMVEC
The same whole cell lysates analyzed via Western Blot for
c-Src (~60 kDa) were also analyzed for human ICAM-1
(~120 kDa), phosphorylated at tyrosine 512 (pTyr512
ICAM-1), total ICAM-1, and β-actin (Figure 6Bi). ICAM-1
phosphorylation in HLMVEC was not significantly altered
by LPS compared to control (p = 0.181, Figure 6Bii),
whereas ICAM-1 expression increased by 144% after incu-
bation with LPS (p = 0.004, Figure 6Biii) and this increase
was significantly attenuated in cells co-incubated with ropi-
vacaine (1 nM, p = 0.028).
Ropivacaine blocks LPS-induced Src-dependent caveolin-1
phosphorylation
HLMVEC lysates incubated with LPS in presence or ab-
sence of different concentrations of ropivacaine were ana-
lyzed by Western blot, focusing on phosphorylated Cav-1
(pTyr14-Cav-1), one of the primary substrates of Src, as
well as the total amount of Cav-1 and β-actin (Figure 6
Ci). LPS-induced increase in pTyr14-Cav-1 (132% of
untreated cells; p < 0.001) was completely abolished by 1
nM ropivacaine (p = 0.003, Figure 6Cii). Neither incuba-
tion of cells with different concentrations of ropivacaine
alone (p = 0.411) nor with LPS (p = 1) significantly al-
tered total Cav-1 expression compared to untreated
cells (Figure 6Ciii).
Active Src is required for endotoxin-induced increase in
ICAM-1 expression
To evaluate whether Src activation is required for the
observed increase in ICAM-1 expression induced by
LPS, we incubated HLMVEC with LPS in absence or
presence of Src kinase inhibitor PP2 shown previously to
effectively block Src activation [13] (Figure 7A). Densi-
tometry analysis (n = 6) confirmed that LPS induced a
139% increase in ICAM-1 expression compared to cells
treated with vehicle alone (DMSO). PP2 blocked the
LPS-induced increase in ICAM-1 expression by 79%
(p = 0.005), but had no effect on ICAM-1 expression in
absence of LPS (p = 1; Figure 7B) indicating LPS-induced
increase in ICAM-1 is mediated in part via Src signaling.
Figure 5 Effect of ropivacaine on acute lung injury in ICAM-1−/− mice. ALI, induced by either hyperinflation (HTV), bacterial lipopolysaccharide
(LPS), or a combination of the two (“double-hit” model) in ICAM-1−/− mice, was assessed by measuring (A) excess lung water (ELW), (B) extravascular
plasma equivalents (EVPE), (C) permeability index, and (D) myeloperoxidase activity as described in Methods. Values shown are mean ± SD with n = 7,
except for MPO activity (n = 3). #p < 0.05 vs. control (NS-NS-HTV); *p < 0.05 vs. LPS-NS-HTV.
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Discussion
The objective of this study was to determine the anti-
inflammatory mechanism of action of the local an-
esthetic ropivacaine using both in vivo and in vitro
approaches. We assessed ALI induced by LPS exposure
or HTV ventilation alone and in combination (i.e.,
“double-hit” model). The combination of the two stimuli
increases the severity of ALI [6], most likely due to addi-
tive effects of mechanical injury and inflammatory cyto-
kine signaling [6,28].
The present study demonstrated that low-dose ropiva-
caine can attenuate ALI induced by LPS or the “double-
hit” of LPS and HTV, but not by HTV ventilation alone.
We also showed that this observed decrease might be
due to an inhibition of LPS-induced Src activation/
expression, ICAM-1 expression, and Cav-1 phospho-
rylation. Our primary objective was to test the effect of
the local anesthetic ropivacaine on HTV ventilation alone
or HTV in combination with bacterial endotoxin as it was
shown previously [9] that ALI induced by “high dose” LPS
Figure 6 Effect of ropivacaine on LPS-induced phosphorylation and expression of Src, ICAM-1, and caveolin-1 in cultured endothelial
cells. Representative Western blots and quantitative densitometry analysis of human lung microvascular endothelial cell (HLMVEC) lysates show
(A) Src, (B) ICAM-1, and (C) Cav-1 after treatment with LPS (4 μg/ml) in absence or presence of ropivacaine at a concentration of 1 nM (10−9 M)
for 4 hours. Quantitative densitometry analysis show (Aii, Bii, Cii) the ratio of phosphorylated over total protein or (Aiii, Biii, Ciii) total protein
over β-actin in cells treated with LPS (4 μg/ml) in absence (black bar) or presence (striped grey bar) of ropivacaine compared to untreated cells
(white bars, set as 1.0). All values shown are mean ± SD (n = 6-11/group). #p < 0.05 vs. untreated cells (control), *p < 0.05 compared to LPS alone.
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(delivered intraperitoneally or intratracheally) could be at-
tenuated by ropivacaine. Changes in vascular permeability
were rather small 4 hours after “low dose” LPS exposure,
which were comparable to those induced by mechanical
ventilation alone [6]. Thus, previous results were con-
firmed by our study.
The combination of two harmful stimuli, LPS and
HTV ventilation, can exponentially increase the severity
of ALI [6], most likely due to additive effects of mechan-
ical injury and inflammatory cytokine signaling [6,28],
which may be relevant to mechanically-ventilated pa-
tients in the intensive care unit setting [29]. We ob-
served a protective effect of ropivacaine only in animals
treated with both stimuli or with LPS alone, whereas
there was no effect of ropivacaine in animals challenged
by HTV ventilation alone, indicating that ropivacaine se-
lectively inhibits inflammatory signaling induced by LPS
in in the lung – independent of ventilation.
The dose of intravenous ropivacaine used in our experi-
mental setting (0.33 mg/kg or 0.01 mg for a 30 g mouse)
was chosen based on previous experiments where this
dose was shown to be effective in attenuating LPS-
induced lung injury [9]. The conversion factor for deter-
mining what the ropivacaine dose in mice would equate
to in humans is approximately 12:1 [30,31], which means
our animal dose would be equivalent to a human dose of
0.027 mg/kg, or a total of 1.89 mg for a 70 kg patient.
Mean (total) plasma concentration of ropivacaine of
1.82 mg/l (5.5 μM) has been reported to be present (and
well-tolerated) in patients after continuous epidural infu-
sions of 0.2% ropivacaine at a rate of 10 mg/hour for
48 hours after major abdominal or urologic surgery [32],
thus indicating the ropivacaine dose used in our study is
clinically relevant. Additionally, the concentrations used
in cell culture experiments were previously proven to have
no effect on the viability of rat lung epithelial and endo-
thelial cells [9] as well as human lung adenocarcinoma
cells [26].
Multiple mechanisms facilitate the transition from the
initial “barotrauma” due to high inspiratory pressures to
the distinct “biotrauma” of VILI [33,34]. Cyclic stretch of
the lung, as in HTV ventilation, leads to a severe physical
injury [33], but at the same time induces inflammatory
signaling locally in alveolar epithelial cells, macrophages,
and neutrophils which together with the direct effect of
stretch on the endothelium, leads to barrier disruption,
pulmonary edema, and neutrophil infiltration into alveo-
lae [4,34]. The results of the present study suggest that
ropivacaine partially blocked inflammatory signaling in-
duced by HTV ventilation, but not the physical injury to
the lung induced by stretch. Although ventilator- and
LPS-induced lung injury share common signaling path-
ways, e.g. Src-dependent caveolin-1 and ICAM-1 signaling
[6,13,19,20,25,35-38], the physical injury induced by HTV
ventilation is much more severe and includes mechanical
disruption of cell membranes and subsequent necrosis
[33,39]. Presumably 60% of the injured cells are able to re-
pair their membrane defects, a process that also involves
inflammatory signaling via the NFκB pathway [33,40].
However, the severity and complexity of the stretch-
induced injury might explain the differences observed bet-
ween Western blots, where activation of inflammatory Src
signaling in vivo and in vitro were shown to be attenuated
by ropivacaine, and in vivo measures of ALI/VILI, where
ropivacaine had no effect on VILI per se. Additionally,
ropivacaine was applied intravenously through a central
venous catheter and therefore the effects were primarily
exerted on endothelial cells. Thus, subsequent in vitro
experiments in this study using human lung microvascular
endothelial cells focused on establishing a molecular
mechanism by which ropivacaine exerts its protective ef-
fects by blocking the signaling events initiated by LPS.
Endothelial hyperpermeability due to barrier dysfunction
of pulmonary capillaries is a key element of the pathoge-
nesis of ALI and ARDS [1]. It was shown previously [9]
Figure 7 Effect of Src inhibitor on LPS-induced ICAM-1 expression
in HLMVEC. (A) Representative Western blot of HLMVEC ICAM-1
(total ICAM-1, row 1) and β-actin (row 2) after treatment of the cells
with either vehicle (dimethylsulfoxide, DMSO 0.1%), Src inhibitor PP2
(pretreatment for 30 minutes at a concentration of 10 μM), LPS
(4 μg/ml), or LPS following pretreatment with PP2. (B) Quantitative
densitometry analysis of the ratio of total ICAM-1 over β-actin. Values
shown are mean ± SEM. #p < 0.05 vs. vehicle (control), *p < 0.05
compared to LPS alone.
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that ALI induced by “high dose” LPS (delivered intraperi-
toneally or intratracheally) could be attenuated by ropiva-
caine. Our results indicated that ropivacaine was only able
to attenuate ALI induced by HTV+ LPS, having no effect
on HTV alone. To gain novel mechanistic insight into the
proposed anti-inflammatory properties of ropivacaine on
inflammation-induced endothelial barrier dysfunction and
lung edema [41], we assessed LPS-induced inflammatory
Src, ICAM-1, and caveolin-1 (Cav-1) signaling in human
lung microvascular endothelial cells (HLMVECs) in vitro.
The observed inhibition of LPS-induced expression/activa-
tion of Src, ICAM-1, and Cav-1 in endothelial cells by
ropivacaine provided significant insight into the possible
anti-inflammatory mechanism and potential therapeutic
benefit of amide-linked local anesthetics on the patho-
genesis of ALI.
We, and others, have shown that Src protein tyrosine
kinase (Src) is a key regulator of endothelial barrier
function. Src-dependent phosphorylation of ICAM-1
tyrosine 512 (human, tyrosine 518 in mice) increases
neutrophil adhesion that can give rise to vascular inflam-
mation [14] and Cav-1-dependent pulmonary vascular
leakage [35]. Additionally, Src phosphorylation of vas-
cular endothelial (VE-) cadherin on two distinct tyrosine
residues (Y658 and Y685) is thought to regulate adhe-
rens junction stability, ultimately resulting in increased
vascular permeability [42-44]. It was also demonstrated
that ropivacaine and lidocaine inhibit inflammatory
endothelial cell Src activation and signaling induced by
TNFα by preventing the initial signaling step down-
stream of TNF receptor-1, thus preventing endothelial
barrier disruption as well as neutrophil adhesion [45].
In the current study, we showed that low-dose ropiva-
caine (1 nM in vitro and 0.01 mg in vivo) lead to a re-
duction in LPS-induced Src expression and activation.
However, we did not observe a significant difference in
LPS-induced Src activity in the animals challenged by
both LPS and hyperinflation, but rather only in animals
exposed to LPS alone. This might be explained by the
fact that the total lung homogenate contains several cell
types (epithelial, endothelial, smooth muscle, fibroblasts,
macrophages etc.) and that each of these cell types may
react differently to LPS, HTV ventilation (and the com-
bination of the two), and ropivacaine in terms of Src
activation.
ICAM-1, a cell surface glycoprotein belonging to the
immunoglobulin superfamily of adhesion molecules, is
expressed in several different cell types including lung
endothelial [16] and epithelial cells [46]. ICAM-1 is re-
quired for firm adhesion of neutrophils to the endothe-
lium and for initiation of transendothelial neutrophil
migration during vascular and systemic inflammation
[16]. Additional experiments with ICAM-1−/− mice in the
present study confirmed that LPS-induced ALI in animals
ventilated with HTV is clearly ICAM-1-dependent,
whereas the lung injury caused by HTV alone might (at
least in part) be independent of ICAM-1 and reflect the
physical cell damage caused by cyclic stretch [33,39,40].
LPS activation of toll-like receptor 4 [6] promotes the re-
lease of inflammatory cytokines which recruit neutrophils
to vascular, interstitial, and alveolar spaces of the lung
[47], thereby leading to inflammatory hyper-permeability
via disruption of the endothelial barrier [35,48].
Interestingly, this investigation also demonstrated that
Src activation is required for the observed increase in
ICAM-1 expression induced by LPS in endothelial cells.
Pre-treatment of cells with the Src inhibitor PP2 signifi-
cantly blocked the increase in ICAM-1 expression, and
thus together with the known requirement of nuclear fac-
tor κB (NF-κB) activation in the mechanism of LPS-
induced increase in ICAM-1 expression [49], Src signaling
also plays a primary role. Consistent with the hypothesis
that Src signaling upstream of NF-κB mediates LPS-
induced ICAM-1 expression, Src activation of NF-κB
was demonstrated in macrophages stimulated with
LPS [50] and in pancreatic acinar cells stimulated with
caerulein [51].
Caveolin-1 is required for formation and trafficking of
caveolae, the primary vesicular carrier and mechanism
of transcellular macromolecule transport (e.g. albumin)
through the vascular endothelial barrier [52,53]. Increa-
singly, evidence points to the role of Cav-1 and caveolae-
mediated transcellular albumin transport (transcytosis) in
the pathogenesis of ALI in general [12,18-20,28,37,54] and
VILI in particular [20], although it could also be shown
that caveolin-1 deficient mice developed a more severe
VILI than WTanimals [22]. In line with the current study,
we previously showed that Src phosphorylation of Cav-1
tyrosine 14 [12] contributes to the development of vas-
cular hyperpermeability via paracellular and transcellular
pathways [19]. Here, we demonstrated that the in-
flammatory signaling mechanisms that promote Cav-1
phosphorylation-dependent increase in transcellular as
well as paracellular permeability during VILI [20,55] were
blocked by ropivacaine. We observed a reduction in both
Src activation and Cav-1 phosphorylation induced by
HTV ventilation in animals treated with ropivacaine,
although this did not abolish HTV (alone) induced
ALI/VILI.
Conclusion
Low dose ropivacaine attenuated ALI induced by LPS
alone as well as in the “double-hit” mouse model induced
by the combination of LPS and hyperinflation, whereas
there was no effect of ropivacaine on VILI induced by
HTV ventilation alone or on ALI induced by the double-
hit protocol in ICAM-1−/− mice. This protective effect of
ropivacaine was associated with a decrease in LPS-induced
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Src activation, ICAM-1 expression, and caveolin-1 phos-
phorylation suggesting that ropivacaine may have signifi-
cant therapeutic potential for treating pulmonary vascular
inflammation and endothelial hyperpermeabilty, thus pre-
venting or tempering the development of ALI.
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